$128.75
5.71%
Nasdaq, Oct 16, 04:28 pm EDT. Closed.
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation

Protagonist Therapeutics, Inc. Classifications & Recommendation

Buy
95%
Hold
5%

Protagonist Therapeutics, Inc. Price Target

Target Price $176.46
Price $128.75
Potential
Number of Estimates 16
16 Analysts have issued a price target Protagonist Therapeutics, Inc. 2027 . The average Protagonist Therapeutics, Inc. target price is $176.46. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 20 analysts: 19 Analysts recommend Protagonist Therapeutics, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Protagonist Therapeutics, Inc. stock has an average upside potential 2027 of . Most analysts recommend the Protagonist Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ ??? ???
??? ???
EBITDA Margin ??? ???
??? ???
Net Margin ??? ???
??? ???

16 Analysts have issued a sales forecast Protagonist Therapeutics, Inc. 2026 . The average Protagonist Therapeutics, Inc. sales estimate is

. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .

This results in the following potential growth metrics:

Revenue Estimates

2025 $46.0m 89.41%
2026
2027
2028
2029
2030
2031
2032
2033

6 Analysts have issued an Protagonist Therapeutics, Inc. EBITDA forecast 2026. The average Protagonist Therapeutics, Inc. EBITDA estimate is

. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-157m 161.33%
2026
2027
2028

EBITDA Margin

2025 -340.83% 678.97%
2026
2027
2028

16 Protagonist Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Protagonist Therapeutics, Inc. net profit estimate is

. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-130m 147.29%
2026
2027
2028
2029
2030
2031
2032
2033

Net Margin

2025 -282.81% 546.46%
2026
2027
2028
2029
2030
2031
2032
2033

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ ??? ???
??? ???
P/E ???
EV/Sales ???

16 Analysts have issued a Protagonist Therapeutics, Inc. forecast for earnings per share. The average Protagonist Therapeutics, Inc. EPS is

. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-2.05 148.46%
2026
2027
2028
2029
2030
2031
2032
2033

P/E ratio

Current 110.99 3.34%
2026
2027
2028
2029
2030
2031
2032
2033

Based on analysts' sales estimates for 2026, the Protagonist Therapeutics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 26.77 15.64%
2026
2027
2028
2029
2030
2031
2032
2033

P/S ratio

Current 29.54 14.18%
2026
2027
2028
2029
2030
2031
2032
2033

Current Protagonist Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
Analyst Rating Date
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today